Phosphorylated tau 217 (p-tau217) is a significant biomarker in the context of Alzheimer’s disease (AD) and other tauopathies.
Diagnostic Accuracy: p-tau217 has demonstrated higher diagnostic accuracy for distinguishing AD from non-AD neurodegenerative disorders.
For example, in cerebrospinal fluid (CSF), p-tau217 showed a 13-fold increase in AD dementia compared to non-AD disorders, with an area outperforming p-tau181 and p-tau231.
Plasma p-tau217 has shown excellent diagnostic performance, with an AUC of 0.96 for differentiating AD from other neurodegenerative diseases.
p-tau217 correlates strongly with amyloid and tau pathology as measured by PET imaging.
It has stronger correlations with amyloid-PET and tau-PET compared to p-tau181, making it a robust indicator of underlying AD pathology.
Longitudinal Monitoring: p-tau217 levels increase during the early stages of AD and are associated with disease progression, cognitive decline, and brain atrophy.
p-tau217 is a valuable biomarker for monitoring disease progression and evaluating the efficacy of therapeutic interventions.
p-tau217 is also effective in differentiating AD from other tauopathies.